Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Earnings per Share (Diluted) : $-3.56 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Earnings per Share (Diluted)?

Alnylam Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.56.

Alnylam Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-1.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.53.

Alnylam Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.77. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.99.

During the past 3 years, the average EPS without NRIGrowth Rate was 28.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -11.70% per year.

During the past 13 years, Alnylam Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 65.60% per year. The lowest was -48.90% per year. And the median was -2.00% per year.

Alnylam Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Alnylam Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Earnings per Share (Diluted) Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-8.11

-7.46

-7.20

-9.30

-3.52

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-1.68	-1.40	-2.21	1.15	-1.10

Competitive Comparison of Alnylam Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Alnylam Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's PE Ratio falls into.

Alnylam Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Alnylam Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-440.242	-	0)	/	124.906
	=	-3.52

Alnylam Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-137.87	-	0)	/	125.623
	=	-1.10

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.56

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Alnylam Pharmaceuticals (NAS:ALNY) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alnylam Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Executives

Michael W Bonney	director	65 HAYDEN AVE, LEXINGTON MA 02421
Pushkal Garg	officer: CMO & EVP Dev & Med Affairs	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Akshay Vaishnaw	officer: SVP, Clinical Research	300 THIRD STREET, CAMBRIDGE MA 02139
Yvonne Greenstreet	officer: EVP, Chief Commercial Officer	PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton	officer: Chief Financial Officer	300 THIRD STREET, CAMBRIDGE MA 02142
Tolga Tanguler	officer: EVP, Chief Commercial Officer	675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Indrani Lall Franchini	officer: EVP, CLO & Secretary	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Dennis A Ausiello	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Phillip A Sharp	director	BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Maraganore	director, officer: President and CEO	75 SIDNEY ST, CAMBRIDGE MA 02139
Laurie Keating	officer: SVP,GC & Secretary	300 THIRD STREET, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285